A molecule worth its weight in gold to fight cancer

Oct 18, 2011
A part of the cisplatin molecule © Benjamin Mills

EPFL scientists have shown that inorganic, metal-containing molecules can be used to fight cancer. The discovery has opened up a whole new area of research.

Chemotherapy treatments often work by attacking the of . The therapy’s effectiveness is often limited, however, because the cancer cells become resistant. In the cell, a protein known as PARP initiates a reaction that repairs the DNA damage the chemotherapy drugs have caused. To reduce this undesirable effect, doctors use complementary treatments. Angela Casini, a researcher in EPFL’s Laboratory of Organometallic and Medicinal Chemistry, and Yury Tsybin of EPFL’s Biomolecular Mass Spectrometry Laboratory have just shown how certain can effectively inhibit the activity of this protein, whose normal job is, ironically, to protect DNA from attack.

Cancer treatments are designed to compromise the DNA of cancer cells. But once the DNA is damaged, the PARP protein jumps into action to protect the cell. It attaches itself to the damaged areas and launches a repair process. The EPFL researchers have shown that metal-based compounds alter the PARP protein, thus inhibiting its repair function. They first studied cisplatin, a drug containing platinum. This drug was already known for its anti-cancer effects, but not for its ability to fight side effects. Then they demonstrated the effectiveness of molecules containing gold. “These new results are very encouraging for getting around the resistance put up by the cancer cells,” says Casini.

Verifying an intuition

Casini followed her chemist’s intuition. “We hypothesized that molecules containing metal in their core were effective PARP inhibitors, based on the elemental chemical properties. But we still needed to verify this experimentally at the molecular level.”

Casini collaborated with Tsybin to run the experiments. They used a high-resolution mass spectrometer, a particularly precise apparatus that allowed them to measure particles in liquid solution, a necessary step in getting the metallic compound to interact with the DNA.

“To understand what interactions are taking place between the various molecules and how they combine, it’s important to know their exact mass, and the mass of their fragments. This allows us to deduce the reactions that are taking place,” explains Tsybin. This is how the scientists were able to figure out how the metallic compound affected the PARP protein.

New therapeutic possibilities

The chemists also hope to be able to open up new areas of research by testing other metallic molecules. Applications for other therapies could be designed using their method. “It’s a gamble, because there’s nothing published on this,” explains Casini. But the huge efforts deployed to fight cancer are testimony to the importance of this particular battle.

Explore further: Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks

More information: Metal-Based Inhibition of Poly(ADP-ribose) Polymerase – The Guardian Angel of DNA, Filipa Mendes, Michael Groessl, Alexey A. Nazarov, Yury O. Tsybin, Gianni Sava, Isabel Santos, Paul J. Dyson, and Angela Casini, Journal of Medicinal Chemistry.

Provided by Ecole Polytechnique Federale de Lausanne

3.5 /5 (6 votes)

Related Stories

Heat helps cancer drugs battle cancer

May 10, 2011

(PhysOrg.com) -- Localized hyperthermia has been used occasionally with cancer drugs for some time, but until now, the reason it helps has been a mystery. In a report in the Proceedings of the National Academy of Sciences, scient ...

New test for ovarian cancer patients

Nov 09, 2010

Scientists have developed a new test to select which patients with ovarian cancer will benefit from new drugs called PARP inhibitors, according to research presented at the National Cancer Research Institute ...

Match your treatment to your cancer

Jun 30, 2011

(Medical Xpress) -- New research has uncovered why certain cancers don’t respond to conventional chemotherapy, highlighting the need to match treatments to cancers better.

Recommended for you

Protein glue shows potential for use with biomaterials

11 hours ago

Researchers at the University of Milan in Italy have shown that a synthetic protein called AGMA1 has the potential to promote the adhesion of brain cells in a laboratory setting. This could prove helpful ...

New tool identifies therapeutic proteins in a 'snap'

Aug 21, 2014

(Phys.org) —In human and bacterial cells, glycosylation – the chemical process of attaching complex sugar molecules to proteins – is as fundamental as it gets, affecting every biological mechanism from cell signaling ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

that_guy
not rated yet Oct 18, 2011
They should be careful with this research...There's a fine line between making chemo more effective, and killing the patient.

No, seriously, people get very sick on chemo because it kills non cancerous cells as well. Making it more effective at that part of its job could easily and quickly make it fatal.

That said, there are other, more targeted therapies, (Like the cancer "vaccines" coming on line) that could benefit from this with less risk.